News - B-TEMIA Inc., a leader in the growing market of human augmentation, announces the appointment of Mr Steven Smith as Vice President Business Development. Mr Smith has extensive industry experience in the home medical equipment market and, in particular, in the commercialization of mobility devices that will be very valuable for the commercialization of KeeogoTM.
News - Medicago, a leading company in the development and production of plant-based vaccines and therapeutics, announced today that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp™, from Mapp Biopharmaceutical.
News - From July 8 to 12, 2015, between 700 and 800 specialists of abdominal obesity, type 2 diabetes, cardiovascular diseases, nutrition and physical activity will take part in this international scientific event. Close to forty speakers are already confirmed.
News - Solvay, a leading global supplier of high-performance thermoplastics, and TSO3 Inc., a leading developer of low-temperature sterilization systems for the healthcare industry, jointly announced that, as part of the U.S. FDA’s 510(k) premarket clearance for TSO3’s new STERIZONE® VP4 Sterilization System received in December 2014, light weight instrument trays made of Solvay Specialty Polymer’s Radel® polyphenylsulfone (PPSU) resin demonstrate strong compatibility for sterilizing a wide range of medical devices.
News - It will soon be possible to diagnose and identify Clostridium difficile, Staphylococcus, Streptococcus, respiratory tract infections, sexually transmitted infections, and a variety of other infectious diseases much faster with cutting edge technology developed by GenePOC, a rapidly expanding Quebec City company.
News - Nordic Life Science Pipeline Inc is proud to officially announce the creation of its new division in biocosmeceutical R&D. Nordic intends to become specialized and to focus mainly on products such as creams composed of medicinal active ingredients capable of significant effects upon vulnerable highly sensitive skin. A few pilot tests in men and women are ready to be launched. By the end of 2015, clinical trials are expected, leading to the commercialization of a first safe and potent product for skin care of people with reduced mobility – e.g., with paralysis.
News - TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that, while pursuing negotiations with potential distribution partners, the Company is strengthening its management team with the addition of two new executives. Mr. James (Jim) Wetzel and Mrs Paule De Blois have joined TSO3, respectively as Vice President of Sales and Marketing and General Manager, Administration. The Company will benefit from the significant experience of these new executives.
News - A young boy in Stoneham owes his sight to the work of a team of researchers from Héma-Québec and a product they developed using a derivative of plasma, the liquid portion of blood that contains a variety of proteins.
News - Debiopharm Diagnostics, part of Debiopharm Group™, is proud to be the lead investor in GenePOC, who are developing a highly innovative, low cost and quick MDx (Molecular Diagnostics) platform. Debiopharm Diagnostics led this investment round together with Emerillon Capital and will become the largest shareholder in GenePOC.
News - Opsens Inc. ("Opsens") (TSXV:OPS) is pleased to announce the first use of its Fractional Flow Reserve ("FFR") products in Europe by the "founding fathers" of FFR, namely Dr. Bernard De Bruyne at the Cardiovascular Center Aalst, Belgium and, shortly, by Professor Nico Pijls, at the Catharina Hospital, Eindhoven the Netherlands. The OptoWire and OptoMonitor are Opsens' products for FFR measurements to optimize the diagnosis and guide the therapy in patients with coronary heart disease.